Targeting c-Rel O-GlcNAcylation and uses thereof
US9696296B2 · kind B2 · utility
1Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 28, 2014 |
| Grant date | Jul 4, 2017 |
| Priority date | — |
| Expiry date | May 14, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2440/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Serine 350 has been identified as the site of O-GlycNAcylation of c-Rel. Methods are provided for identifying compositions capable of blocking c-Rel activation. The methods generally involve identifying compounds that inhibit O-GlcNAcylation of c-Rel at the serine 350 residue, thereby preventing c-Rel activation and production of c-Rel-dependent cytokines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.